Form 4 for FENC FENNEC PHARMACEUTICALS INC.
Accepted 2026-08-28 17:42:18 ET · period of report 2026-08-27 · accession 0001468308-26-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-28 17:42 | 2026-08-27 | FENC | Andrade Robert | CFO | S - Sale+OE | $11.78 | -75.0K | 217.7K | -26% | -$883.5K |
| DT | 2026-08-28 17:42 | 2026-08-28 | FENC | Andrade Robert | CFO | M - OptEx | $5.10 | +21.9K | 239.6K | +10% | +$111.8K |
| DT | 2026-08-28 17:42 | 2026-08-28 | FENC | Andrade Robert | CFO | M - OptEx | $0.00 | -21.9K | 779.3K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares | 2026-08-27 | S | D | 75,000 | $11.78 | 217,675 | D | — | — | (F1) Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). A portion of the sales proceeds from this transaction will be used by the reporting person to pay tax obligations of the reporting person. |
| 2 | Common | Common shares | 2026-08-28 | M | A | 21,928 | $5.10 | 239,603 | D | — | — | (F2) Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027. |
| 3 | Derivative | Stock Options | 2026-08-28 | M | D | 21,928 | $0.00 | 779,330 | D | $5.10 · 2017-06-27 to 2027-06-27 | 21,928 Common Shares | (F2) Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027. |